HRP20110201T1 - Spojevi i sastavi kao inhibitori proteaze kanalizirane aktivacije - Google Patents
Spojevi i sastavi kao inhibitori proteaze kanalizirane aktivacije Download PDFInfo
- Publication number
- HRP20110201T1 HRP20110201T1 HR20110201T HRP20110201T HRP20110201T1 HR P20110201 T1 HRP20110201 T1 HR P20110201T1 HR 20110201 T HR20110201 T HR 20110201T HR P20110201 T HRP20110201 T HR P20110201T HR P20110201 T1 HRP20110201 T1 HR P20110201T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- image
- compound
- optionally substituted
- 6alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 35
- 230000003213 activating effect Effects 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 11
- 150000003839 salts Chemical class 0.000 claims abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 9
- 125000003118 aryl group Chemical group 0.000 claims abstract 7
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract 6
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 6
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 4
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 2
- 125000001425 triazolyl group Chemical group 0.000 claims abstract 2
- 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 claims 6
- 102100032471 Transmembrane protease serine 4 Human genes 0.000 claims 6
- 102000035195 Peptidases Human genes 0.000 claims 5
- 108091005804 Peptidases Proteins 0.000 claims 5
- 239000004365 Protease Substances 0.000 claims 5
- 230000004913 activation Effects 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102100022046 Brain-specific serine protease 4 Human genes 0.000 claims 2
- 108010059081 Cathepsin A Proteins 0.000 claims 2
- 102000005572 Cathepsin A Human genes 0.000 claims 2
- 108091006146 Channels Proteins 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 101000897856 Homo sapiens Adenylyl cyclase-associated protein 2 Proteins 0.000 claims 2
- 101000896891 Homo sapiens Brain-specific serine protease 4 Proteins 0.000 claims 2
- 101000836079 Homo sapiens Serpin B8 Proteins 0.000 claims 2
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 claims 2
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 claims 2
- 101000637855 Homo sapiens Transmembrane protease serine 11E Proteins 0.000 claims 2
- 101000798707 Homo sapiens Transmembrane protease serine 13 Proteins 0.000 claims 2
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims 2
- 101000798700 Homo sapiens Transmembrane protease serine 3 Proteins 0.000 claims 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 2
- 108010028275 Leukocyte Elastase Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108010091175 Matriptase Proteins 0.000 claims 2
- 101100069392 Mus musculus Gzma gene Proteins 0.000 claims 2
- 102100033174 Neutrophil elastase Human genes 0.000 claims 2
- 102100032001 Transmembrane protease serine 11E Human genes 0.000 claims 2
- 102100032467 Transmembrane protease serine 13 Human genes 0.000 claims 2
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 claims 2
- 108090000631 Trypsin Proteins 0.000 claims 2
- 102000004142 Trypsin Human genes 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 229960003910 promethazine Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000012588 trypsin Substances 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000025678 Ciliary Motility disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 1
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 1
- 101000598054 Homo sapiens Transmembrane protease serine 11B Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- MYEJFUXQJGHEQK-ALRJYLEOSA-N Proscillaridin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 MYEJFUXQJGHEQK-ALRJYLEOSA-N 0.000 claims 1
- 102100037023 Transmembrane protease serine 11B Human genes 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000037427 ion transport Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009266 primary ciliary dyskinesia Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- -1 C1- 6alkyl Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88433407P | 2007-01-10 | 2007-01-10 | |
US89147407P | 2007-02-23 | 2007-02-23 | |
PCT/US2007/085366 WO2008085608A1 (en) | 2007-01-10 | 2007-11-21 | Compounds and compositions as channel activating protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110201T1 true HRP20110201T1 (hr) | 2011-08-31 |
Family
ID=39148650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110201T HRP20110201T1 (hr) | 2007-01-10 | 2011-03-18 | Spojevi i sastavi kao inhibitori proteaze kanalizirane aktivacije |
Country Status (33)
Country | Link |
---|---|
US (1) | US20080176901A1 (sr) |
EP (2) | EP2104535B9 (sr) |
JP (1) | JP2010515729A (sr) |
KR (1) | KR101084787B1 (sr) |
AR (1) | AR064841A1 (sr) |
AT (1) | ATE493174T1 (sr) |
AU (1) | AU2007342223B2 (sr) |
BR (1) | BRPI0720799A2 (sr) |
CA (1) | CA2673803A1 (sr) |
CL (1) | CL2008000060A1 (sr) |
CO (1) | CO6190626A2 (sr) |
CU (1) | CU23762B7 (sr) |
CY (1) | CY1111340T1 (sr) |
DE (1) | DE602007011670D1 (sr) |
DK (1) | DK2104535T3 (sr) |
EA (1) | EA016199B1 (sr) |
EC (1) | ECSP099517A (sr) |
GT (1) | GT200900196A (sr) |
HK (1) | HK1129860A1 (sr) |
HN (1) | HN2009001282A (sr) |
HR (1) | HRP20110201T1 (sr) |
MA (1) | MA31037B1 (sr) |
MX (1) | MX2009007476A (sr) |
NO (1) | NO20092817L (sr) |
NZ (1) | NZ577939A (sr) |
PE (1) | PE20081566A1 (sr) |
PL (1) | PL2104535T3 (sr) |
PT (1) | PT2104535E (sr) |
RS (1) | RS51644B (sr) |
SV (1) | SV2009003330A (sr) |
TN (1) | TN2009000294A1 (sr) |
TW (1) | TW200845981A (sr) |
WO (1) | WO2008085608A1 (sr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137080A2 (en) | 2006-05-23 | 2007-11-29 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
EP2118062A1 (en) | 2007-01-10 | 2009-11-18 | F. Hoffmann-Roche AG | Sulfonamide derivatives as chymase inhibitors |
CA2677487A1 (en) * | 2007-02-09 | 2008-08-14 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
MX2011011332A (es) | 2009-05-18 | 2011-11-18 | Orion Corp | Inhibidores de proteasas. |
GB201805174D0 (en) * | 2018-03-29 | 2018-05-16 | Univ Leeds Innovations Ltd | Compounds |
US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
BR112021018456A2 (pt) * | 2019-03-22 | 2021-11-23 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento |
US20220354833A1 (en) | 2019-09-17 | 2022-11-10 | Mereo Biopharma 4 Limited | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
IL293551A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
IL293550A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
CA3159159A1 (en) * | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
IL297211A (en) | 2020-04-16 | 2022-12-01 | Mereo Biopharma 4 Ltd | Methods involving the neutrophil elastase inhibitor albalstat for the treatment of respiratory disease mediated by alpha-1 antitrypsin deficiency |
CA3234399A1 (en) | 2021-10-20 | 2023-04-27 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
WO2023183405A2 (en) * | 2022-03-22 | 2023-09-28 | Alexion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
WO1993018007A1 (en) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
WO1993019750A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating allergic or inflammatory diseases |
US5552438A (en) | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
ZA951617B (en) * | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
US5726159A (en) * | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
US5707966A (en) * | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
US5705487A (en) * | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
US5914319A (en) * | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
GB2299455B (en) * | 1995-03-31 | 1999-12-22 | Motorola Inc | Self phased antenna element with dielectric and associated method |
AU3496297A (en) * | 1996-06-25 | 1998-01-14 | Eli Lilly And Company | Anticoagulant agents |
GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
BR9815931A (pt) | 1998-06-30 | 2001-02-20 | Dow Chemical Co | Polióis poliméricos, um processo para sua produção, e espuma de poliuretanoobtida |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
HUP0203528A3 (en) | 1999-05-04 | 2003-11-28 | Schering Corp | Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use |
KR100439358B1 (ko) | 1999-05-04 | 2004-07-07 | 쉐링 코포레이션 | Ccr5 길항제로서 유용한 피페라진 유도체 |
US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
EA006685B1 (ru) | 1999-08-21 | 2006-02-24 | Алтана Фарма Аг | Синергетическая композиция |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
HUP0300832A2 (hu) | 2000-04-27 | 2003-08-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
ES2213703T5 (es) | 2000-06-27 | 2011-11-02 | Laboratorios S.A.L.V.A.T., S.A. | Carbamatos derivados de arilalquilaminas. |
GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
WO2002012265A1 (en) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP1345937B1 (en) | 2000-12-22 | 2005-09-28 | Almirall Prodesfarma AG | Quinuclidine carbamate derivatives and their use as m3 antagonists |
ES2266291T3 (es) | 2000-12-28 | 2007-03-01 | Almirall Prodesfarma Ag | Nuevos derivados de quinuclidina y composiciones medicinales que los contienen. |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
SI1383786T1 (sl) | 2001-04-30 | 2009-02-28 | Glaxo Group Ltd | Protivnetni 17.beta-karbotioatestrski derivati androstana s ciklično estrsko skupino na položaju 17.alfa |
ES2307751T3 (es) | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
EP2327765B1 (en) | 2001-06-21 | 2015-04-01 | BASF Enzymes LLC | Nitrilases |
CA2462200A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
PL393155A1 (pl) | 2001-09-14 | 2011-03-28 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
US7361668B2 (en) | 2001-10-17 | 2008-04-22 | Ucb, S.A. | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
AU2002356759A1 (en) | 2001-12-01 | 2003-06-17 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
CN1832948B (zh) | 2001-12-20 | 2011-06-15 | 基耶西药品股份公司 | 1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途 |
WO2003072592A1 (en) | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
WO2003062259A2 (en) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
ES2298508T3 (es) | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
WO2003082787A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE60335869D1 (de) | 2002-04-11 | 2011-03-10 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
ES2298511T3 (es) | 2002-04-25 | 2008-05-16 | Glaxo Group Limited | Derivados de fenetanolamina. |
EP1507754A1 (en) | 2002-05-28 | 2005-02-23 | Theravance, Inc. | Alkoxy aryl beta-2 adrenergic receptor agonists |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
DE60312520T2 (de) | 2002-06-25 | 2007-11-22 | Merck Frosst Canada Ltd., Kirkland | 8-(biaryl)chinolin-pde4-inhibitoren |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
WO2004005258A1 (en) | 2002-07-02 | 2004-01-15 | Merck Frosst Canada & Co. | Di-aryl-substituted-ethane pyridone pde4 inhibitors |
PT1521733E (pt) | 2002-07-08 | 2014-10-29 | Pfizer Prod Inc | Moduladores do recetor de glucocorticoides |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
US20060167001A1 (en) | 2002-08-10 | 2006-07-27 | Sterk Jan G | Pyridazinone-derivatives as pde4 inhibitors |
JP4555684B2 (ja) | 2002-08-10 | 2010-10-06 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pde4阻害剤としての、ピロリジンジオンにより置換されたピペリジン−フタラゾン |
AU2003255376A1 (en) | 2002-08-10 | 2004-03-11 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
CA2494643A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
US20060116518A1 (en) | 2002-08-17 | 2006-06-01 | Altana Pharma Ag | Novel phenanthridines |
PL373598A1 (en) | 2002-08-17 | 2005-09-05 | Altana Pharma Ag | Novel benzonaphthyridines |
EP1532113B1 (en) | 2002-08-21 | 2008-08-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
EP1534675B1 (en) | 2002-08-23 | 2009-02-25 | Ranbaxy Laboratories, Ltd. | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists |
KR20050036982A (ko) | 2002-08-29 | 2005-04-20 | 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 | 염증, 알러지 및 증식성 질환의 치료에 글루코코르티코이드모사체로 사용하기 위한 3-(설폰아미도에틸)-인돌 유도체 |
ES2281658T3 (es) | 2002-08-29 | 2007-10-01 | Nycomed Gmbh | 3-hidroxi-6-fenilfenantridinas como inhibidores de pde-4. |
WO2004019944A1 (en) | 2002-08-29 | 2004-03-11 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規6−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
CN1688577A (zh) | 2002-09-18 | 2005-10-26 | 小野药品工业株式会社 | 三氮杂螺[5.5]十一烷衍生物及以它为活性成分的药物 |
WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規1−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
KR20050047552A (ko) | 2002-10-11 | 2005-05-20 | 화이자 인코포레이티드 | 베타-2 작용제로서의 인돌 유도체 |
EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
US20060205790A1 (en) | 2002-10-22 | 2006-09-14 | Coe Diane M | Medicinal arylethanolamine compounds |
EP1554262B1 (en) | 2002-10-23 | 2007-12-05 | Glenmark Pharmaceuticals Limited | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
PL377122A1 (pl) | 2002-10-28 | 2006-01-23 | Glaxo Group Limited | Pochodne fenetanoloaminy do leczenia chorób układu oddechowego |
GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
US7019019B2 (en) | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
AU2004207482B2 (en) | 2003-01-21 | 2009-10-08 | Merck Sharp & Dohme Corp. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
GB0507577D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
-
2007
- 2007-11-21 AU AU2007342223A patent/AU2007342223B2/en not_active Ceased
- 2007-11-21 PT PT07854747T patent/PT2104535E/pt unknown
- 2007-11-21 PL PL07854747T patent/PL2104535T3/pl unknown
- 2007-11-21 DE DE602007011670T patent/DE602007011670D1/de active Active
- 2007-11-21 EP EP07854747A patent/EP2104535B9/en active Active
- 2007-11-21 RS RS20110129A patent/RS51644B/sr unknown
- 2007-11-21 KR KR1020097014455A patent/KR101084787B1/ko not_active IP Right Cessation
- 2007-11-21 NZ NZ577939A patent/NZ577939A/en not_active IP Right Cessation
- 2007-11-21 EP EP10013675A patent/EP2279777A2/en not_active Withdrawn
- 2007-11-21 AT AT07854747T patent/ATE493174T1/de active
- 2007-11-21 CA CA002673803A patent/CA2673803A1/en not_active Abandoned
- 2007-11-21 WO PCT/US2007/085366 patent/WO2008085608A1/en active Application Filing
- 2007-11-21 DK DK07854747.8T patent/DK2104535T3/da active
- 2007-11-21 JP JP2009545545A patent/JP2010515729A/ja not_active Ceased
- 2007-11-21 US US11/943,845 patent/US20080176901A1/en not_active Abandoned
- 2007-11-21 BR BRPI0720799-9A patent/BRPI0720799A2/pt not_active IP Right Cessation
- 2007-11-21 EA EA200900920A patent/EA016199B1/ru not_active IP Right Cessation
- 2007-11-21 MX MX2009007476A patent/MX2009007476A/es active IP Right Grant
-
2008
- 2008-01-10 TW TW097101044A patent/TW200845981A/zh unknown
- 2008-01-10 CL CL200800060A patent/CL2008000060A1/es unknown
- 2008-01-10 PE PE2008000105A patent/PE20081566A1/es not_active Application Discontinuation
- 2008-01-10 AR ARP080100104A patent/AR064841A1/es not_active Application Discontinuation
-
2009
- 2009-06-30 MA MA32060A patent/MA31037B1/fr unknown
- 2009-07-08 GT GT200900196A patent/GT200900196A/es unknown
- 2009-07-08 TN TNP2009000294A patent/TN2009000294A1/fr unknown
- 2009-07-08 HN HN2009001282A patent/HN2009001282A/es unknown
- 2009-07-10 CU CU20090122A patent/CU23762B7/es not_active IP Right Cessation
- 2009-07-10 SV SV2009003330A patent/SV2009003330A/es not_active Application Discontinuation
- 2009-07-13 CO CO09072488A patent/CO6190626A2/es not_active Application Discontinuation
- 2009-07-15 EC EC2009009517A patent/ECSP099517A/es unknown
- 2009-08-10 NO NO20092817A patent/NO20092817L/no not_active Application Discontinuation
- 2009-10-09 HK HK09109366.8A patent/HK1129860A1/xx not_active IP Right Cessation
-
2011
- 2011-03-14 CY CY20111100283T patent/CY1111340T1/el unknown
- 2011-03-18 HR HR20110201T patent/HRP20110201T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110201T1 (hr) | Spojevi i sastavi kao inhibitori proteaze kanalizirane aktivacije | |
RU2008150615A (ru) | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы | |
RU2008150613A (ru) | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы | |
ES2201484T3 (es) | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. | |
UA104997C2 (uk) | Аміди азотвмісних насичених гетероциклів та 3,5-діаміно-6-хлор-2-піразинкарбонової кислоти як лікарський засіб | |
CN103687488B (zh) | 化学和代谢稳定的具有钠通道阻滞剂活性的二肽 | |
HRP20201790T1 (hr) | Konjugati cisteinom izmijenjenih antitijela | |
ES2374130T3 (es) | Bloqueantes de los canales de sodio. | |
AU2019200171B2 (en) | Thiosaccharide mucolytic agents | |
ES2691805T3 (es) | Medicamento para el tratamiento de una enfermedad ocular | |
JP2012211188A (ja) | 新規なキャップ化ピラジノイルグアニジンナトリウムチャネル遮断薬 | |
CN105073717A (zh) | 可用于治疗由黏膜水化不足造成的疾病的氯-吡嗪甲酰胺衍生物 | |
AU2007294547A2 (en) | Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes | |
AU2005278080A1 (en) | Soluble amide and ester pyrazinoylguanidine sodium channel blockers | |
TR201809148T4 (tr) | Göz kuruluğu ve diğer mukozal hastalıkların tedavisi için sodyum kanal blokör etkinliğine sahip dendrimer benzeri amino asitler. | |
ES2381672T3 (es) | Preparación en solución acuosa que comprende un antibiótico aminoglicósido y bromfenaco | |
US10981943B2 (en) | Antimicrobial compounds, compositions, and uses thereof | |
MEP42908A (en) | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds | |
TR200101028T2 (tr) | 2,3-Diikameli piridin türevi, bunun hazırlanmasında kullanılan proses, bunu içeren farmasötik terkip ve ara maddesi | |
CN104955812A (zh) | 经芳烷基和芳氧基烷基取代的上皮钠通道阻断化合物 | |
AR044014A1 (es) | Composiciones farmaceuticas para administracion intranasal de acido [2-(8,9-dioxo-2, 6-diazabiciclo [5.2.0) non-1 (7) -en-2-il)alquil]-fosfonico y derivados y metodos de utilizacion de las mismas | |
CA3164300A1 (en) | Compounds and their use for the treatment of .alpha.1-antitrypsin deficiency | |
JP2023505587A (ja) | 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用 | |
CN108721295A (zh) | 肺病症和其他病症的治疗 | |
JPWO2020023910A5 (sr) |